Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBC-103 in MPS IIIB
NCT02618512Phase 2Terminated
- Sponsor
- Alexion Pharmaceuticals
- Start
- Oct 2015
- Primary completion
- Aug 2017
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lesinidase alfa in mucopolysaccharidosis type IIIB, sponsored by Alexion Pharmaceuticals. Primary endpoint: Safety and Tolerability of SBC-103 at 96 weeks. Started Oct 2015; status: terminated.
02
Drugs
lesinidase alfa
03
Conditions
mucopolysaccharidosis type IIIB
Beyond the preview
Go deeper on NCT02618512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02618512.